IEC issues corporate update on Kubby
Cryogenics
TEMECULA, CA -- Oct 30, 2017 -- InvestorsHub NewsWire --
International Endeavors Corporation ( OTC : IDVV )
("IEC") today announced updates on KUBBY Cryogenics, Inc.,
subsidiary partner of IEC, and biomedical cannabis research and
development firm.
Kubby Cryogenics manufacturing division produces a unique
biomedicine from the raw cannabis plant. This new class of
medicine, the Kubby Cryogenics method, is the company's own
proprietary method capturing the vitality of the raw plant in its
extraction process. This small batch, apothecary approach captures
the live resins that have medical benefits for a number of
ailments, including: cancer, inflammatory disease, epilepsy, brain
injury, autism, Alzheimer's, and more.
Currently research being done focuses on the medical value in
specific strains that may be used in the company's proprietary
Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is
working with genetic partners to secure several medicinal strains
to patent for this use. Most people of all ages can potentially use
Kubby Cryogenics because it's naturally a non-psychoactive
product.
"Our Cryogenic process appears to trigger the production of
Adult Stem Cells, based on independent research on the
Endocannabinoid system and the entourage effect," said Steve Kubby,
CEO and President of Kubby Cryogenics. According to a recent peer
reviewed study, the endocannabinoid system directs cell fate
specification of Neural Stem Cells in the Central Nervous System,
which can lead to new cell generation in the brain and the
periphery systems. (https://www.ncbi.nlm.nih.gov/pubmed/24076098
and 24256257)
Kubby Cryogenics is in the process of gathering information from
its research and testimonials of patients. We plan to develop a
website shortly that will focus on Kubby Cryogenics and its
efforts.
Cryogenics Medical Uses
Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy,
Brain Injury, Stroke, Inflammation, and PTSD.
Mr. Steve Kubby Bio
Steven Wynn "Steve" Kubby played a key role in the passage of
California Proposition 215, a ballot initiative passed in 1996 to
legalize medical marijuana. He is a well-known cancer patient of 36
years, who benefits his recovery through the use of
non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby
was formally Chairman and CEO of Cannabis Sativa Inc., traded under
the symbol CBDS, and has authored 2 books on drug policy reform.
Mr. Kubby's distinguished political career includes runs for
Governor of California in 1998, and the 2008 Presidential primary
race under the libertarian ticket.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on
biomedical uses of non-psychoactive cannabis based products for the
treatment of a wide variety of illnesses. Through a unique patent
pending Cryogenic process, the Company can process different unique
medical grade cannabis strains that are genetically profiled to
treating specific diseases. www.internationalendeavorscorp.com
Forward-Looking Statements are included within the meaning of
Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements
regarding our expected future financial position, results of
operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities,
plans and objectives of management for future operations, including
words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other
similar expressions are forward-looking statements and involve
risks, uncertainties and contingencies, many of which are beyond
our control, which may cause actual results, performance, or
achievements to differ materially from anticipated results,
performance, or achievements. International Endeavors Corporation
(IDVV)
is under no obligation to (and expressly disclaim any such
obligation to) update or alter our forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT INFORMATION
Contact: Nobia Kubby
Chief Operations Officer
Phone: 831-383-2141
Email: Nobia@kubbyinc.com